CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 258 filers reported holding CRISPR THERAPEUTICS AG in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $62,729 | -19.1% | 1,382 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $77,586 | +24.1% | 1,382 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $62,508 | +11.3% | 1,382 | 0.0% | 0.00% | +33.3% |
| Q4 2022 | $56,178 | -39.6% | 1,382 | -2.9% | 0.00% | -50.0% |
| Q3 2022 | $93,000 | +6.9% | 1,424 | -1.0% | 0.01% | +20.0% |
| Q2 2022 | $87,000 | -3.3% | 1,439 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $90,000 | -17.4% | 1,439 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $109,000 | -32.3% | 1,439 | 0.0% | 0.01% | -44.4% |
| Q3 2021 | $161,000 | -30.9% | 1,439 | 0.0% | 0.01% | -25.0% |
| Q2 2021 | $233,000 | +67.6% | 1,439 | +26.3% | 0.01% | +50.0% |
| Q1 2021 | $139,000 | -12.0% | 1,139 | +10.3% | 0.01% | -20.0% |
| Q4 2020 | $158,000 | +83.7% | 1,033 | 0.0% | 0.01% | +66.7% |
| Q3 2020 | $86,000 | +11.7% | 1,033 | -1.9% | 0.01% | 0.0% |
| Q2 2020 | $77,000 | +92.5% | 1,053 | +13.0% | 0.01% | +50.0% |
| Q1 2020 | $40,000 | – | 932 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |